Chung, K.F., Wenzel, S.E., Brozek, J.L., Bush, A., Castro, M., Sterk, P.J., Adcock, I.M., Bateman, E.D., Bel, E.H., Bleecker, E.R., Boulet, L.-P., Brightling, C., Chanez, P., Dahlen, S.-E., Djukanovic, R., Frey, U., Gaga, M., Gibson, P., Hamid, Q., Jajour, N.N., Mauad, T., Sorkness, R.L., Teague, W.G., International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur. Respir. J. 43:2 (2014), 343–373, 10.1183/09031936.00202013.
Sullivan, P.W., Ghushchyan, V.H., Slejko, J.F., Belozeroff, V., Globe, D.R., Lin, S.L., The burden of adult asthma in the United States: Evidence from the Medical Expenditure Panel Survey. 363–369 e3 J. Allergy Clin. Immunol., 127, 2011, 10.1016/j.jaci.2010.10.042.
Kaur, R., Chupp, G., Phenotypes and endotypes of adult asthma: Moving toward precision medicine. J. Allergy Clin. Immunol. 144 (2019), 1–12, 10.1016/j.jaci.2019.05.031.
Chung, K.F., Precision medicine in asthma: linking phenotypes to targeted treatments. Curr. Opin. Pulmon. Med., 24, 2018 https://journals.lww.com/co-pulmonarymedicine/Fulltext/2018/01000/Precision_medicine_in_asthma__linking_phenotypes.3.aspx.
Licona-Limon, P., Kim, L.K., Palm, N.W., Flavell, R.A., TH2, allergy and group 2 innate lymphoid cells. Nat. Immunol. 14 (2013), 536–542, 10.1038/ni.2617.
Godar, M., Blanchetot, C., de Haard, H., Lambrecht, B.N., Brusselle, G., Personalized medicine with biologics for severe type 2 asthma: current status and future prospects. MAbs 10 (2018), 34–45, 10.1080/19420862.2017.1392425.
W. Busse, J. Corren, B.Q. Lanier, M. McAlary, A. Fowler-Taylor, G. Della Cioppa, A. van As, N. Gupta, Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma, J. Allergy Clin Immunol. 108 (2001) 184–190. doi:https://doi.org/10.1067/mai.2001.117880.
Katsaounou, P., Buhl, R., Brusselle, G., Pfister, P., Martínez, R., Wahn, U., Bousquet, J., Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma. Respir. Med. 150 (2019), 51–62, 10.1016/j.rmed.2019.02.003.
Haldar, P., Brightling, C.E., Hargadon, B., Gupta, S., Monteiro, W., Sousa, A., Marshall, R.P., Bradding, P., Green, R.H., Wardlaw, A.J., Pavord, I.D., Mepolizumab and exacerbations of refractory eosinophilic asthma. N. Engl. J. Med. 360 (2009), 973–984, 10.1056/NEJMoa0808991.
Castro, M., Zangrilli, J., Wechsler, M.E., Bateman, E.D., Brusselle, G.G., Bardin, P., Murphy, K., Maspero, J.F., O'Brien, C., Korn, S., Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir. Med. 3 (2015), 355–366, 10.1016/S2213-2600(15)00042-9.
FitzGerald, J.M., Bleecker, E.R., Nair, P., Korn, S., Ohta, K., Lommatzsch, M., Ferguson, G.T., Busse, W.W., Barker, P., Sproule, S., Gilmartin, G., Werkström, V., Aurivillius, M., Goldman, M., Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 388 (2016), 2128–2141, 10.1016/S0140-6736(16)31322-8.
Castro, M., Corren, J., Pavord, I.D., Maspero, J., Wenzel, S., Rabe, K.F., Busse, W.W., Ford, L., Sher, L., FitzGerald, J.M., Katelaris, C., Tohda, Y., Zhang, B., Staudinger, H., Pirozzi, G., Amin, N., Ruddy, M., Akinlade, B., Khan, A., Chao, J., Martincova, R., Graham, N.M.H., Hamilton, J.D., Swanson, B.N., Stahl, N., Yancopoulos, G.D., Teper, A., Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. New Engl. J. Med. 378 (2018), 2486–2496, 10.1056/NEJMoa1804092.
Fahy, J.V., Type 2 inflammation in asthma – present in most, absent in many. Nat. Rev. Immunol. 15 (2014), 57–65, 10.1038/nri3786.
Woodruff, P.G., Modrek, B., Choy, D.F., Jia, G., Abbas, A.R., Ellwanger, A., Arron, J.R., Koth, L.L., Fahy, J.V., T-helper type 2–driven inflammation defines major subphenotypes of asthma. Am. J. Respir. Crit. Care Med. 180 (2009), 388–395, 10.1164/rccm.200903-0392OC.
Swedin, L., Saarne, T., Rehnberg, M., Glader, P., Niedzielska, M., Johansson, G., Hazon, P., Catley, M.C., Patient stratification and the unmet need in asthma. Pharmacol. Ther. 169 (2017), 13–34, 10.1016/j.pharmthera.2016.06.016.
Leckie, M.J., ten Brinke, A., Khan, J., Diamant, Z., O'Connor, B.J., Walls, C.M., Mathur, A.K., Cowley, H.C., Chung, K.F., Djukanovic, R., Hansel, T.T., Holgate, S.T., Sterk, P.J., Barnes, P.J., Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic response. Lancet 356 (2000), 2144–2148, 10.1016/S0140-6736(00)03496-6.
Pavord, I.D., Korn, S., Howarth, P., Bleecker, E.R., Buhl, R., Keene, O.N., Ortega, H., Chanez, P., Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 380 (2012), 651–659, 10.1016/S0140-6736(12)60988-X.
Nair, P., Pizzichini, M.M., Kjarsgaard, M., Inman, M.D., Efthimiadis, A., Pizzichini, E., Hargreave, F.E., O'Byrne, P.M., Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N. Engl. J. Med. 360 (2009), 985–993, 10.1056/NEJMoa0805435.
Simpson, J.L., Scott, R., Boyle, M.J., Gibson, P.G., Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology 11 (2006), 54–61, 10.1111/j.1440-1843.2006.00784.x.
Schleich, F.N., Manise, M., Sele, J., Henket, M., Seidel, L., Louis, R., Distribution of sputum cellular phenotype in a large asthma cohort: predicting factors for eosinophilic vs neutrophilic inflammation. BMC Pulm. Med., 13, 2013, 11, 10.1186/1471-2466-13-11.
Hoyte, F.C.L., Gross, L.M., Katial, R.K., Exhaled nitric oxide: an update. Immunol. Allergy Clin. North Am. 38 (2018), 573–585, 10.1016/j.iac.2018.06.001.
Heaney, L.G., Cough and severe asthma. Pulm. Pharmacol. Ther. 47 (2017), 72–76, 10.1016/j.pupt.2017.10.002.
Schauberger, E., Peinhaupt, M., Cazares, T., Lindsley, A.W., Lipid mediators of allergic disease: pathways, treatments, and emerging therapeutic targets. Curr. Allergy Asthma Rep., 16, 2016, 48, 10.1007/s11882-016-0628-3.
Trinh, H.K.T., Lee, S.-H., Cao, T.B.T., Park, H.-S., Asthma pharmacotherapy: an update on leukotriene treatments. Exp. Rev. Respir. Med. 13 (2019), 1169–1178, 10.1080/17476348.2019.1670640.
Peters, U., Dixon, A.E., Forno, E., Obesity and asthma. J. Allergy Clin. Immunol. 141 (2018), 1169–1179, 10.1016/j.jaci.2018.02.004.
Castillo, J.R., Peters, S.P., Busse, W.W., Asthma exacerbations: pathogenesis, prevention, and treatment. J. Allergy Clin. Immunol. Pr. 5 (2017), 918–927, 10.1016/j.jaip.2017.05.001.
McBrien, C.N., Menzies-Gow, A., The biology of eosinophils and their role in asthma. Front Med., 4, 2017, 93 https://www.frontiersin.org/article/10.3389/fmed.2017.00093.
Klion, A.D., Ackerman, S.J., Bochner, B.S., Contributions of eosinophils to human health and disease. Annu. Rev. Pathol. Mech. Dis. 15 (2020), 179–209, 10.1146/annurev-pathmechdis-012419-032756.
